Product Description
Mechanisms of Action: GABA Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Hong Kong | Malaysia | Norway | Poland | South Africa
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/20/2024 |
PubMed |
Licence change for Zoletil. |
|
03/26/2024 |
PubMed |
Ketamine-butorphanol-medetomidine for the immobilisation of free-living hyenas (Crocuta crocuta). |
|
02/19/2024 |
PubMed |
Tiletamine-Zolazepam, Ketamine, and Xylazine Anesthetic Protocol for High-Quality, High-Volume Spay and Neuter of Free-Roaming Cats in Seoul, Korea. |